The global revenue from the systemic sclerosis treatment market stands at US$ 928.1 Million in 2022, with the global market expected to grow at a CAGR of 7.9% to reach a valuation of US$ 2.2 Billion by the end of 2033. According to a recent study by Future Market Insights, drug therapy are leading the market with a share of about 95.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Size (2023) | US$ 1.0 Billion |
| Projected Market Value (2033) | US$ 2.2 Billion |
| Global Market Growth Rate (2023 to 2033) | 7.9% CAGR |
| Market Share of Top 5 Countries | 67.4% |
| Key Players | fizer Inc.; Sanofi S.A; Cipla Ltd; Accord Healthcare Inc.; Organon LLC; Zydus Lifescience Ltd.; Teva Pharmaceutical Industries Ltd.; Novartis AG; Boehringer Ingelheim Pharmaceuticals, Inc; Amgen Inc; F. Hoffmann-La Roche Ltd; Bayer Healthcare LLC; Johnson & Johnson Services Inc.; Lupin Ltd; GlaxoSmithKline Plc; Medtronic Plc |
Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities. The prevalence of systemic sclerosis is increasing globally, driving the demand for effective treatment options. As awareness and diagnosis of the disease improve, the market for systemic sclerosis treatments is expected to expand. The introduction of these emerging therapies expands the market and offers hope for improved disease management.
The systemic sclerosis treatment market is expanding in emerging economies due to improving healthcare infrastructure, rising healthcare expenditure, and increased access to specialized care. This expansion presents growth opportunities for systemic sclerosis treatment providers and pharmaceutical companies.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 7.4% in the last 4 years from 2018 to 2022. Global market systemic sclerosis treatment is around 1.4% of the US$ 68.1 billion global autoimmune disease therapeutics market in 2022, in terms of value share.
Scleroderma, a rare connective tissue disease, affects multiple organs including joints, muscles, skin, and organs. Despite its chronic nature, effective treatment and management strategies enable individuals with scleroderma to lead fulfilling and productive lives, creating opportunities for comprehensive healthcare solutions within this niche market.
The diagnosis of sclerosis can be challenging due to the variability of symptoms and the potential for overlapping with other conditions. Nevertheless, advancements in medical technology and diagnostic techniques have greatly enhanced the accuracy of diagnosis. Magnetic resonance imaging (MRI) is widely utilized to identify and visualize the distinct.
Lesions in the brain and spinal cord that are associated with sclerosis. These advancements have significantly contributed to improving the diagnostic process for sclerosis.
The increasing prevalence of systemic scleroderma worldwide can be attributed to a variety of factors, including genetics, environmental factors, immune system dysfunction, and other factors.
The severity and progression of systemic sclerosis vary among individuals. Patients with more severe symptoms, organ involvement, or rapid disease progression require more intensive treatment regimens. The demand for systemic sclerosis treatment is higher among patients with advanced stages of the disease or those experiencing significant symptoms and complications.
The range of available treatment options plays a significant role in determining demand. Patients and healthcare professionals seek diverse therapeutic choices to address the complex nature of systemic sclerosis. The availability of disease-modifying therapies, immunosuppressants, vasodilators, and supportive care interventions influences the demand for systemic sclerosis treatment.
It has been observed that genetic factors may contribute to the vulnerability of individuals towards autoimmune diseases. There exists a correlation between specific genes and an elevated likelihood of systemic scleroderma. With the advancement of genetic studies, a greater number of individuals with a genetic predisposition may be identified, which could potentially lead to an increase in prevalence rates.
Hence, the global systemic scleroderma treatment market is being driven by the high prevalence and incidence rate of the disease worldwide.
Principal Consultant
A standardized framework is necessary for the assessment of therapeutics for systemic scleroderma, which must be adhered to during the evaluation of the disease.
Economic conditions, such as recessions or economic downturns, can influence the demand for systemic sclerosis treatment. Financial constraints and reduced healthcare budgets may affect patients' ability to access and afford treatments, potentially impacting market growth. The availability and extent of reimbursement and insurance coverage for systemic sclerosis treatments can influence demand. If certain treatments are not adequately covered or reimbursed by insurance providers, it may limit patient access and impact the growth of the treatment market.
Regulatory policies, including drug approval processes, pricing regulations, and intellectual property rights, can impact the growth of systemic sclerosis treatment. Delays in regulatory approvals or changes in pricing regulations may affect the availability and affordability of treatments, potentially impacting market growth.
However, research funding and collaboration among academic institutions, pharmaceutical companies, and government organizations play a crucial role in advancing systemic sclerosis treatment options. Adequate funding and collaborative research efforts can lead to the development of innovative therapies, driving market growth.
With an overall CAGR of 8.4%, the United States has contributed for around 47.2% to the North American market share in 2022.
The trend towards customized medical care and targeted therapeutics is having an effect on the management of systemic sclerosis. While the organization based in USA, are focusing on tailored treatment approaches based on individual patient characteristics, disease subtype, and organ involvement can be developed with an improved understanding of the disease's heterogeneity.
There is potential for more effective and personalized treatment strategies through the development of targeted therapies that address specific mechanisms or pathways implicated in systemic sclerosis.
Japan has contributed for around 5.6% to the global market share in 2022.
Japan's regulatory pathways have been optimized to facilitate the approval and market entry of treatments for systemic sclerosis, resulting in a faster process. The Japanese government's provision of incentives to promote research and development in rare diseases, such as systemic sclerosis, is encouraging innovation and investment in the market.
The provision of unambiguous directives by regulatory agencies regarding clinical trial design, endpoints, and data requisites has been instrumental in streamlining the process of developing and accessing treatments for systemic sclerosis.
The healthcare system in Japan provides adequate reimbursement for treatments related to systemic sclerosis, which serves as a driving force for market expansion and facilitates the availability of cutting-edge therapies.
China held a market share of about 5.3% within the global market in 2022.
The aim of this collaboration was to enhance research and development activities for the production of top-notch generic and complex generic medicines. Which will ultimately reduce the cost of the medicines required for the treatment.
Recent developments in medical research and development in China have included the exploration of autoimmune diseases such as systemic sclerosis. The conducted research has resulted in the emergence of novel treatment alternatives and therapeutic approaches, thereby expanding the scope of possibilities for patients to cope with their medical condition efficiently.
Based on current research trends, it is anticipated that there will be a rise in demand for treatments related to systemic sclerosis.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The drug therapy segment held around 95.4% share of the global market in 2022.
Immunosuppressants function by either hindering the function of specific immune cells or reducing the production of immune system components. The aforementioned medications have the potential to mitigate symptoms, decelerate the advancement of the disease, and impede additional harm to bodily organs. It is common practice to utilize them in conjunction with other treatments, such as corticosteroids, to effectively address the symptoms and potential complications associated with systemic scleroderma.
Immunosuppressants can be a highly effective treatment option so, it is a dominant segment in the therapeutic category.
The limited cutaneous systemic sclerosis segment held around 68.2% share of the total market in 2022.
Genetic factors, environmental triggers, and variations in immune response may play a role in the development of different subtypes of systemic sclerosis.
It's important to note that while limited cutaneous systemic sclerosis may have a higher incidence among the scleroderma types, limited cutaneous systemic sclerosis can cause significant morbidity and can affect various organ systems.
The skin fibrosis segment had around 26.1% of the global market in 2022. The global systemic sclerosis market is worth US$ 242.1 million in total.
Skin involvement is a prominent characteristic of systemic sclerosis and is observed in nearly all patients with systemic sclerosis, with varying degrees and severity.
The injectable segment has contributed for around 47.7% of the global market share in 2022.
For systemic sclerosis treatment, certain medications like immunosuppressants or disease-modifying antirheumatic drugs (DMARDs) may have better efficacy when administered through intravenous or subcutaneous routes.
The rapid and targeted delivery of medication can enhance its therapeutic effects. It indicates that injectable medications have the potential to provide a more direct and efficient delivery of drugs into the bloodstream, as they bypass the digestive system.
This can help to prevent any degradation or alteration of the drug that may occur during oral administration. This particular route of administration may offer increased bioavailability and more consistent drug levels within the body. Which makes it a better option to have than any other route of administration.
The hospital pharmacies a share of about 41.4% in 2022, within the global market in 2022.
Hospitals pharmacies have robust systems in place which can substantially reduce the medication error, like the verification of the dosages and how to use it which helps reduce the risk of the accidents like over dosages and ensure patient safety.
The market for systemic sclerosis treatment has a fair amount of competition. The key players in the market are also putting a lot of effort into expanding their presence in emerging markets with new partnerships and merger acquisitions also focusing on launching new technologically advanced products. The competitive environment includes an analysis of a few global and local businesses that control the market shares. Along with acquisitions and mergers and partnerships with key market players.
Some key instances of development include:
Similarly, the team at Future Market Insights has tracked recent developments related to companies in the systemic sclerosis treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa. |
| Key Countries Covered | USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, Nordic, , India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Therapeutics, Indication, Target Organ, Route of Administration, Distribution Channel and Region |
| Key Companies Covered | Medtronic Plc; GlaxoSmithKline Plc; Lupin Ltd; Johnson & Johnson Services Inc.; Bayer Healthcare LLC; F. Hoffmann-La Roche Ltd; Amgen Inc; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Zydus Lifescience Ltd.; Organon LLC; Accord Healthcare Inc.; Pfizer, Inc.; Sanofi S.A.; Cipla Ltd. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The systemic sclerosis treatment market size is US$ 2.2 billion in 2023.
The systemic sclerosis treatment market is anticipated to showcase a 7.9% CAGR between 2023 and 2033.
Treatments for systemic sclerosis encompass drug therapy, primarily immunosuppressants, and hematopoietic stem cell transplantation.
The United States commands the market due to its robust 8.4% CAGR, driven by advanced research and increasing patient awareness.
The aging population, rising awareness, and improved healthcare infrastructure contribute to the increased demand.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Disease Epidemiology 4.2. Pipeline Assessment 4.3. Regulatory Landscape 4.4. Reimbursement Outlook 4.5. Treatment Adoption Analysis 4.6. PESTLE Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Market Outlook 5.1.2. Global Rise in Healthcare Spending 5.2. Forecast Factors - Relevance & Impact 5.2.1. Technological Advancements 5.2.2. Regulatory Framework 5.2.3. Strategic Mergers and Acquisitions by Manufacturers 5.2.4. Increasing Demand for Generic Products 5.2.5. Cross-licensing to broaden the service offerings 5.2.6. Unmet Need for Treatments of Multiple Sclerosis 5.2.7. Frequency of Product Approvals 5.2.8. Growing Product Pipeline 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Therapeutics, 2018 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapeutics, 2023 to 2033 7.3.1. By Drugs Therapy 7.3.1.1. Corticosteroids 7.3.1.2. Immunosuppressant 7.3.1.3. Nonsteroidal Anti-inflammatory Drugs 7.3.1.4. Blood Pressure Medication 7.3.1.5. Proton Pump Inhibitors 7.3.1.6. TNF Inhibitors 7.3.1.7. Light Therapy 7.3.1.8. Nitroglycerin Ointment 7.3.1.9. Others 7.3.2. Hematopoietic Stem Cell Transplantation (HSCT) 7.4. Market Attractiveness Analysis By Therapeutics 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 8.3.1. Limited Cutaneous Systemic Sclerosis 8.3.2. Diffuse Cutaneous Systemic Sclerosis 8.4. Market Attractiveness Analysis By Indication 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Target Organ 9.1. Introduction 9.2. Historical Market Size (US$ Million) Analysis By Target Organ, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Target Organ, 2023 to 2033 9.3.1. Skin Fibrosis 9.3.2. Musculoskeletal 9.3.3. Digital Ulcers 9.3.4. Pulmonary Arterial Hypertension 9.3.5. Gastrointestinal 9.3.6. Pulmonary Fibrosis 9.3.7. Scleroderma Renal Crisis 9.4. Market Attractiveness Analysis By Target Organ 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 10.1. Introduction 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 10.3.1. Injectable 10.3.2. Oral 10.3.3. Topical 10.4. Market Attractiveness Analysis By Route of Administration 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 11.3.1. Hospital Pharmacies 11.3.2. Specialty Clinics 11.3.3. Retail Pharmacies 11.3.4. Online Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. USA 13.3.1.2. Canada 13.3.2. By Therapeutics 13.3.3. By Indication 13.3.4. By Target Organ 13.3.5. By Route of Administration 13.3.6. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Therapeutics 13.4.3. By Indication 13.4.4. By Target Organ 13.4.5. By Route of Administration 13.4.6. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. USA Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Therapeutics 13.8.1.2.2. By Indication 13.8.1.2.3. By Target Organ 13.8.1.2.4. By Route of Administration 13.8.1.2.5. By Distribution Channel 13.8.2. Canada Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Therapeutics 13.8.2.2.2. By Indication 13.8.2.2.3. By Target Organ 13.8.2.2.4. By Route of Administration 13.8.2.2.5. By Distribution Channel 14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. Mexico 14.3.1.2. Brazil 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Therapeutics 14.3.3. By Indication 14.3.4. By Target Organ 14.3.5. By Route of Administration 14.3.6. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Therapeutics 14.4.3. By Indication 14.4.4. By Target Organ 14.4.5. By Route of Administration 14.4.6. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Mexico Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Therapeutics 14.8.1.2.2. By Indication 14.8.1.2.3. By Target Organ 14.8.1.2.4. By Route of Administration 14.8.1.2.5. By Distribution Channel 14.8.2. Brazil Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Therapeutics 14.8.2.2.2. By Indication 14.8.2.2.3. By Target Organ 14.8.2.2.4. By Route of Administration 14.8.2.2.5. By Distribution Channel 14.8.3. Argentina Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Therapeutics 14.8.3.2.2. By Indication 14.8.3.2.3. By Target Organ 14.8.3.2.4. By Route of Administration 14.8.3.2.5. By Distribution Channel 15. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. UK 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Nordic 15.3.1.9. Rest of Europe 15.3.2. By Therapeutics 15.3.3. By Indication 15.3.4. By Target Organ 15.3.5. By Route of Administration 15.3.6. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Therapeutics 15.4.3. By Indication 15.4.4. By Target Organ 15.4.5. By Route of Administration 15.4.6. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. Germany Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Therapeutics 15.8.1.2.2. By Indication 15.8.1.2.3. By Target Organ 15.8.1.2.4. By Route of Administration 15.8.1.2.5. By Distribution Channel 15.8.2. Italy Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Therapeutics 15.8.2.2.2. By Indication 15.8.2.2.3. By Target Organ 15.8.2.2.4. By Route of Administration 15.8.2.2.5. By Distribution Channel 15.8.3. France Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Therapeutics 15.8.3.2.2. By Indication 15.8.3.2.3. By Target Organ 15.8.3.2.4. By Route of Administration 15.8.3.2.5. By Distribution Channel 15.8.4. UK Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast by Market Taxonomy 15.8.4.2.1. By Therapeutics 15.8.4.2.2. By Indication 15.8.4.2.3. By Target Organ 15.8.4.2.4. By Route of Administration 15.8.4.2.5. By Distribution Channel 15.8.5. Spain Market Analysis 15.8.5.1. Introduction 15.8.5.2. Market Analysis and Forecast by Market Taxonomy 15.8.5.2.1. By Therapeutics 15.8.5.2.2. By Indication 15.8.5.2.3. By Target Organ 15.8.5.2.4. By Route of Administration 15.8.5.2.5. By Distribution Channel 15.8.6. BENELUX Market Analysis 15.8.6.1. Introduction 15.8.6.2. Market Analysis and Forecast by Market Taxonomy 15.8.6.2.1. By Therapeutics 15.8.6.2.2. By Indication 15.8.6.2.3. By Target Organ 15.8.6.2.4. By Route of Administration 15.8.6.2.5. By Distribution Channel 15.8.7. Russia Market Analysis 15.8.7.1. Introduction 15.8.7.2. Market Analysis and Forecast by Market Taxonomy 15.8.7.2.1. By Therapeutics 15.8.7.2.2. By Indication 15.8.7.2.3. By Target Organ 15.8.7.2.4. By Route of Administration 15.8.7.2.5. By Distribution Channel 15.8.8. Nordic Market Analysis 15.8.8.1. Introduction 15.8.8.2. Market Analysis and Forecast by Market Taxonomy 15.8.8.2.1. By Therapeutics 15.8.8.2.2. By Indication 15.8.8.2.3. By Target Organ 15.8.8.2.4. By Route of Administration 15.8.8.2.5. By Distribution Channel 16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Therapeutics 16.3.3. By Indication 16.3.4. By Target Organ 16.3.5. By Route of Administration 16.3.6. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Therapeutics 16.4.3. By Indication 16.4.4. By Target Organ 16.4.5. By Route of Administration 16.4.6. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. China Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Therapeutics 16.8.1.2.2. By Indication 16.8.1.2.3. By Target Organ 16.8.1.2.4. By Route of Administration 16.8.1.2.5. By Distribution Channel 16.8.2. Japan Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Therapeutics 16.8.2.2.2. By Indication 16.8.2.2.3. By Target Organ 16.8.2.2.4. By Route of Administration 16.8.2.2.5. By Distribution Channel 16.8.3. South Korea Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Therapeutics 16.8.3.2.2. By Indication 16.8.3.2.3. By Target Organ 16.8.3.2.4. By Route of Administration 16.8.3.2.5. By Distribution Channel 17. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. India 17.3.1.2. Indonesia 17.3.1.3. Malaysia 17.3.1.4. Thailand 17.3.1.5. Rest of South Asia 17.3.2. By Therapeutics 17.3.3. By Indication 17.3.4. By Target Organ 17.3.5. By Route of Administration 17.3.6. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Therapeutics 17.4.3. By Indication 17.4.4. By Target Organ 17.4.5. By Route of Administration 17.4.6. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. India Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Therapeutics 17.8.1.2.2. By Indication 17.8.1.2.3. By Target Organ 17.8.1.2.4. By Route of Administration 17.8.1.2.5. By Distribution Channel 17.8.2. Indonesia Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Therapeutics 17.8.2.2.2. By Indication 17.8.2.2.3. By Target Organ 17.8.2.2.4. By Route of Administration 17.8.2.2.5. By Distribution Channel 17.8.3. Malaysia Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Therapeutics 17.8.3.2.2. By Indication 17.8.3.2.3. By Target Organ 17.8.3.2.4. By Route of Administration 17.8.3.2.5. By Distribution Channel 17.8.4. Thailand Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Therapeutics 17.8.4.2.2. By Indication 17.8.4.2.3. By Target Organ 17.8.4.2.4. By Route of Administration 17.8.4.2.5. By Distribution Channel 18. Oceania Market 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Therapeutics 18.3.3. By Indication 18.3.4. By Target Organ 18.3.5. By Route of Administration 18.3.6. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Therapeutics 18.4.3. By Indication 18.4.4. By Target Organ 18.4.5. By Route of Administration 18.4.6. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. Australia Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Therapeutics 18.8.1.2.2. By Indication 18.8.1.2.3. By Target Organ 18.8.1.2.4. By Route of Administration 18.8.1.2.5. By Distribution Channel 18.8.2. New Zealand Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Therapeutics 18.8.2.2.2. By Indication 18.8.2.2.3. By Target Organ 18.8.2.2.4. By Route of Administration 18.8.2.2.5. By Distribution Channel 19. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Türkiye 19.3.1.3. Northern Africa 19.3.1.4. South Africa 19.3.1.5. Rest of Middle East and Africa 19.3.2. By Therapeutics 19.3.3. By Indication 19.3.4. By Target Organ 19.3.5. By Route of Administration 19.3.6. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Therapeutics 19.4.3. By Indication 19.4.4. By Target Organ 19.4.5. By Route of Administration 19.4.6. By Distribution Channel 19.5. Market Trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. GCC Countries Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Therapeutics 19.8.1.2.2. By Indication 19.8.1.2.3. By Target Organ 19.8.1.2.4. By Route of Administration 19.8.1.2.5. By Distribution Channel 19.8.2. Türkiye Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Therapeutics 19.8.2.2.2. By Indication 19.8.2.2.3. By Target Organ 19.8.2.2.4. By Route of Administration 19.8.2.2.5. By Distribution Channel 19.8.3. Northern Africa Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Therapeutics 19.8.3.2.2. By Indication 19.8.3.2.3. By Target Organ 19.8.3.2.4. By Route of Administration 19.8.3.2.5. By Distribution Channel 19.8.4. South Africa Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Therapeutics 19.8.4.2.2. By Indication 19.8.4.2.3. By Target Organ 19.8.4.2.4. By Route of Administration 19.8.4.2.5. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Concentration 20.4. Market Presence Analysis 20.4.1. Regional Footprint Analysis 20.4.2. Product Footprint Analysis 20.4.3. Channel Footprint Analysis 21. Competition Analysis 21.1. Competition Dashboard 21.2. Branding and Promotional Strategies, Key Players 21.3. Key Development Analysis 21.4. Competition Deep Dive 21.4.1. Pfizer Inc. 21.4.1.1. Overview 21.4.1.2. Product Portfolio 21.4.1.3. Sales Footprint 21.4.1.4. Key Developments 21.4.1.5. SWOT Analysis 21.4.1.6. Strategy Overview 21.4.1.6.1. Marketing Strategies 21.4.1.6.2. Product Strategies 21.4.1.6.3. Channel Strategies 21.4.2. Sanofi S.A 21.4.2.1. Overview 21.4.2.2. Product Portfolio 21.4.2.3. Sales Footprint 21.4.2.4. Key Developments 21.4.2.5. SWOT Analysis 21.4.2.6. Strategy Overview 21.4.2.6.1. Marketing Strategies 21.4.2.6.2. Product Strategies 21.4.2.6.3. Channel Strategies 21.4.3. Cipla Ltd 21.4.3.1. Overview 21.4.3.2. Product Portfolio 21.4.3.3. Sales Footprint 21.4.3.4. Key Developments 21.4.3.5. SWOT Analysis 21.4.3.6. Strategy Overview 21.4.3.6.1. Marketing Strategies 21.4.3.6.2. Product Strategies 21.4.3.6.3. Channel Strategies 21.4.4. Accord Healthcare Inc. 21.4.4.1. Overview 21.4.4.2. Product Portfolio 21.4.4.3. Sales Footprint 21.4.4.4. Key Developments 21.4.4.5. SWOT Analysis 21.4.4.6. Strategy Overview 21.4.4.6.1. Marketing Strategies 21.4.4.6.2. Product Strategies 21.4.4.6.3. Channel Strategies 21.4.5. Organon LLC 21.4.5.1. Overview 21.4.5.2. Product Portfolio 21.4.5.3. Sales Footprint 21.4.5.4. Key Developments 21.4.5.5. SWOT Analysis 21.4.5.6. Strategy Overview 21.4.5.6.1. Marketing Strategies 21.4.5.6.2. Product Strategies 21.4.5.6.3. Channel Strategies 21.4.6. Zydus Lifescience Ltd. 21.4.6.1. Overview 21.4.6.2. Product Portfolio 21.4.6.3. Sales Footprint 21.4.6.4. Key Developments 21.4.6.5. SWOT Analysis 21.4.6.6. Strategy Overview 21.4.6.6.1. Marketing Strategies 21.4.6.6.2. Product Strategies 21.4.6.6.3. Channel Strategies 21.4.7. Teva Pharmaceutical Industries Ltd. 21.4.7.1. Overview 21.4.7.2. Product Portfolio 21.4.7.3. Sales Footprint 21.4.7.4. Key Developments 21.4.7.5. SWOT Analysis 21.4.7.6. Strategy Overview 21.4.7.6.1. Marketing Strategies 21.4.7.6.2. Product Strategies 21.4.7.6.3. Channel Strategies 21.4.8. Novartis AG 21.4.8.1. Overview 21.4.8.2. Product Portfolio 21.4.8.3. Sales Footprint 21.4.8.4. Key Developments 21.4.8.5. SWOT Analysis 21.4.8.6. Strategy Overview 21.4.8.6.1. Marketing Strategies 21.4.8.6.2. Product Strategies 21.4.8.6.3. Channel Strategies 21.4.9. Boehringer Ingelheim Pharmaceuticals, Inc 21.4.9.1. Overview 21.4.9.2. Product Portfolio 21.4.9.3. Sales Footprint 21.4.9.4. Key Developments 21.4.9.5. SWOT Analysis 21.4.9.6. Strategy Overview 21.4.9.6.1. Marketing Strategies 21.4.9.6.2. Product Strategies 21.4.9.6.3. Channel Strategies 21.4.10. Amgen Inc 21.4.10.1. Overview 21.4.10.2. Product Portfolio 21.4.10.3. Sales Footprint 21.4.10.4. Key Developments 21.4.10.5. SWOT Analysis 21.4.10.6. Strategy Overview 21.4.10.6.1. Marketing Strategies 21.4.10.6.2. Product Strategies 21.4.10.6.3. Channel Strategies 21.4.11. F. Hoffmann-La Roche Ltd 21.4.11.1. Overview 21.4.11.2. Product Portfolio 21.4.11.3. Sales Footprint 21.4.11.4. Key Developments 21.4.11.5. SWOT Analysis 21.4.11.6. Strategy Overview 21.4.11.6.1. Marketing Strategies 21.4.11.6.2. Product Strategies 21.4.11.6.3. Channel Strategies 21.4.12. Bayer Healthcare LLC 21.4.12.1. Overview 21.4.12.2. Product Portfolio 21.4.12.3. Sales Footprint 21.4.12.4. Key Developments 21.4.12.5. SWOT Analysis 21.4.12.6. Strategy Overview 21.4.12.6.1. Marketing Strategies 21.4.12.6.2. Product Strategies 21.4.12.6.3. Channel Strategies 21.4.13. Johnson & Johnson Services Inc. 21.4.13.1. Overview 21.4.13.2. Product Portfolio 21.4.13.3. Sales Footprint 21.4.13.4. Key Developments 21.4.13.5. SWOT Analysis 21.4.13.6. Strategy Overview 21.4.13.6.1. Marketing Strategies 21.4.13.6.2. Product Strategies 21.4.13.6.3. Channel Strategies 21.4.14. Lupin Ltd 21.4.14.1. Overview 21.4.14.2. Product Portfolio 21.4.14.3. Sales Footprint 21.4.14.4. Key Developments 21.4.14.5. SWOT Analysis 21.4.14.6. Strategy Overview 21.4.14.6.1. Marketing Strategies 21.4.14.6.2. Product Strategies 21.4.14.6.3. Channel Strategies 21.4.15. GlaxoSmithKline Plc 21.4.15.1. Overview 21.4.15.2. Product Portfolio 21.4.15.3. Sales Footprint 21.4.15.4. Key Developments 21.4.15.5. SWOT Analysis 21.4.15.6. Strategy Overview 21.4.15.6.1. Marketing Strategies 21.4.15.6.2. Product Strategies 21.4.15.6.3. Channel Strategies 21.4.16. Medtronic Plc 21.4.16.1. Overview 21.4.16.2. Product Portfolio 21.4.16.3. Sales Footprint 21.4.16.4. Key Developments 21.4.16.5. SWOT Analysis 21.4.16.6. Strategy Overview 21.4.16.6.1. Marketing Strategies 21.4.16.6.2. Product Strategies 21.4.16.6.3. Channel Strategies 22. Assumptions and Acronyms Used 23. Research Methodology
Healthcare
March 2023
REP-GB-16811
298 pages
Explore Healthcare Insights
View Reports
Systemic Sclerosis Treatment Market
